ID   HBL-1 [Human diffuse large B-cell lymphoma]
AC   CVCL_4213
SY   HBL1
DR   BTO; BTO:0002522
DR   CLO; CLO_0037256
DR   BioGRID_ORCS_Cell_line; 747
DR   cancercelllines; CVCL_4213
DR   Cosmic; 1486586
DR   Cosmic; 1487545
DR   Cosmic; 1517652
DR   Cosmic; 2129634
DR   Cosmic; 2437308
DR   GEO; GSM1035338
DR   GEO; GSM1059804
DR   GEO; GSM1374489
DR   GEO; GSM1890017
DR   GEO; GSM1890018
DR   GEO; GSM1890019
DR   GEO; GSM1890020
DR   GEO; GSM2037050
DR   GEO; GSM2037051
DR   Progenetix; CVCL_4213
DR   Wikidata; Q54881426
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2854303;
RX   PubMed=3338018;
RX   PubMed=8558920;
RX   PubMed=15028022;
RX   PubMed=20054396;
RX   PubMed=21179087;
RX   PubMed=23257783;
RX   PubMed=26787899;
RX   PubMed=29416618;
RX   PubMed=29666304;
RX   PubMed=30165192;
RX   PubMed=31510952;
CC   Population: Japanese.
CC   Doubling time: ~48 hours (PubMed=3338018).
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Mutation; HGNC; 1699; CD79B; Simple; p.Tyr196Phe (c.587A>T); Zygosity=Heterozygous (PubMed=20054396).
CC   Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=21179087).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C36081; Diffuse large B-cell lymphoma activated B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 25
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2854303; DOI=10.1620/tjem.156.319;
RA   Nozawa Y., Abe M., Wakasa H., Ohno H., Fukuhara S., Kinoshita T.,
RA   Osato T.;
RT   "Establishment and characterization of an Epstein-Barr virus negative
RT   B-cell lymphoma cell line and successful heterotransplantation.";
RL   Tohoku J. Exp. Med. 156:319-330(1988).
//
RX   PubMed=3338018; DOI=10.1002/1097-0142(19880201)61:3<483::AID-CNCR2820610313>3.0.CO;2-L;
RA   Abe M., Nozawa Y., Wakasa H., Ohno H., Fukuhara S.;
RT   "Characterization and comparison of two newly established Epstein-Barr
RT   virus-negative lymphoma B-cell lines. Surface markers, growth
RT   characteristics, cytogenetics, and transplantability.";
RL   Cancer 61:483-490(1988).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x;
RA   Kamimura K., Hojo H., Abe M.;
RT   "Characterization of expression of protein kinase C isozymes in human
RT   B-cell lymphoma: relationship between its expression and prognosis.";
RL   Pathol. Int. 54:224-230(2004).
//
RX   PubMed=20054396; DOI=10.1038/nature08638;
RA   Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B.,
RA   Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. III,
RA   Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A.,
RA   Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M.,
RA   Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H.,
RA   Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pierce S.K., Staudt L.M.;
RT   "Chronic active B-cell-receptor signalling in diffuse large B-cell
RT   lymphoma.";
RL   Nature 463:88-92(2010).
//
RX   PubMed=21179087; DOI=10.1038/nature09671;
RA   Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H.,
RA   Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. III, Romesser P.,
RA   Wright G., Powell J.I., Rosenwald A., Muller-Hermelink H.-K., Ott G.,
RA   Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S.,
RA   Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Staudt L.M.;
RT   "Oncogenically active MYD88 mutations in human lymphoma.";
RL   Nature 470:115-119(2011).
//
RX   PubMed=23257783; DOI=10.1038/leu.2012.367;
RA   Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H.,
RA   Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S.,
RA   Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.;
RT   "MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.";
RL   Leukemia 27:1381-1390(2013).
//
RX   PubMed=26787899; DOI=10.1073/pnas.1524677113;
RA   Dekker J.D., Park D., Shaffer A.L. III, Kohlhammer H., Deng W.,
RA   Lee B.-K., Ippolito G.C., Georgiou G., Iyer V.R., Staudt L.M.,
RA   Tucker H.O.;
RT   "Subtype-specific addiction of the activated B-cell subset of diffuse
RT   large B-cell lymphoma to FOXP1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016).
//
RX   PubMed=29416618; DOI=10.18632/oncotarget.20378;
RA   Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C.,
RA   Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr.,
RA   Pham L.V.;
RT   "Preclinical efficacy and biological effects of the oral proteasome
RT   inhibitor ixazomib in diffuse large B-cell lymphoma.";
RL   Oncotarget 9:346-360(2018).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//
RX   PubMed=30165192; DOI=10.1016/j.canlet.2018.08.020;
RA   Qu C.-J., Kunkalla K., Vaghefi A., Frederiksen J.K., Liu Y.-D.,
RA   Chapman J.R., Blonska M., Bernal-Mizrachi L., Alderuccio J.P.,
RA   Lossos I.S., Landgraf R., Vega-Vazquez F.;
RT   "Smoothened stabilizes and protects TRAF6 from degradation: a novel
RT   non-canonical role of smoothened with implications in lymphoma
RT   biology.";
RL   Cancer Lett. 436:149-158(2018).
//
RX   PubMed=31510952; DOI=10.1186/s12885-019-6129-8;
RA   Takashima Y., Yoshimura T., Kano Y., Hayano A., Hondoh H., Ikenaka K.,
RA   Yamanaka R.;
RT   "Differential expression of N-linked oligosaccharides in
RT   methotrexate-resistant primary central nervous system lymphoma
RT   cells.";
RL   BMC Cancer 19:910.1-910.11(2019).
//